Tirzepatide
SURMOUNT-1
Eli Lilly · Phase 3 · Completed · Enrollment 2539
Y axis: Change in body weight from baseline, %
X axis: Weeks since randomization
Cited trial source. Only weeks the source states.
- Placebo, one timepoint
- 5 mg Tirzepatide, one timepoint
- 10 mg Tirzepatide, one timepoint
- 15 mg Tirzepatide, one timepoint
- Placebo: week 72 -3.1%
- 5 mg Tirzepatide: week 72 -15%
- 10 mg Tirzepatide: week 72 -19.5%
- 15 mg Tirzepatide: week 72 -20.9%
One reported week is a point at that week. It is not a line from 0%. A solid line connects two or more reported weeks.